I-Corps: Bioengineered Chimeric Antigen Receptor (CAR) Chips for Screening CAR T-Cell Immunotherapy

I-Corps项目更广泛的影响/商业潜力是开发嵌合抗原受体（CAR） t细胞芯片技术，以提高癌症治疗的成功率，缩短CAR - t细胞免疫治疗的周期，使整个方法具有成本效益，并最终改善患者的福利。这项技术可能对资源匮乏的社区尤其有影响，因为目前的CAR - t细胞治疗是负担不起的。此外，CAR- t芯片技术可能为药物开发提供范式转变：降低开发成本，提高新开发的CAR- t细胞产品在临床试验中的总体通过率。I-Corps项目的基础是开发一种改进的CAR- t细胞疗法，对骨髓中多种进化免疫抑制环境进行全面分析，并建立一个强大的系统来探测CAR- t细胞与肿瘤免疫微环境之间的相互作用。目前，常规的体外细胞培养和动物模型用于研究b细胞急性淋巴母细胞淋巴瘤（B-ALL）的病理生理和测试CAR - t细胞的功能。这些方法不能概括人类免疫系统，因此它们的临床全面应用。新的基于微流体的CAR- t芯片平台可以通过在芯片上重现患者特异性白血病骨髓微环境，为筛选和改进CAR- t细胞治疗提供新的途径。提出的技术可以快速、经济、高通量地评估患者对CAR -t细胞免疫疗法的特异性反应，以及其他治疗方法。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is the development of Chimeric Antigen Receptor (CAR) T-cell Chip technology to improve the success rate of cancer treatment and shorten the cycle of CAR T-cell immunotherapy, making the entire approach cost-effective and ultimately improving patient welfare. This technology may be especially impactful in low resource communities where current CAR T-cell treatments are unaffordable. Moreover, the CAR-T Chip technology may provide a paradigm shift in drug development: reducing development costs and improving the overall pass rate of newly developed CAR T-cell products in clinical trials. This I-Corps project is based on the development of an improved CAR T-cell therapy with a holistic analysis of the diverse, evolutionary immunosuppressive milieus in the bone marrow and a robust system to probe the interactions between CAR-T cells and the tumor immune microenvironment. Currently, conventional in vitro cell culture and animal models are used to study B-cell acute lymphoblastic lymphoma (B-ALL) pathophysiology and test CAR T-cell functionality. These methods fail to recapitulate the human immune system and thus their clinical full-flanged usage. The new microfluidics-based CAR-T Chip platform may provide a new avenue for screening and improving CAR T-cell therapy by recapitulating patient-specific leukemic bone marrow microenvironment on a chip. The proposed technology may enable a rapid, cost-effective, and high-throughput evaluation of patient-specific response to CAR T-cell immunotherapy, as well as alternative treatments.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.